AGO4A Antibody

What is AGO4 and why is it important to use specific antibodies in antiviral research?

AGO4 is one of four mammalian Argonaute proteins (AGO1-4) that function as effectors in RNA interference (RNAi) and microRNA (miRNA) pathways. Unlike AGO1 and AGO3, AGO4 plays a unique and essential role in mammalian antiviral defense against multiple viral types in immune cells and in vivo models. Proper antibody selection is critical as AGO4-deficient cells display marked hyper-susceptibility to virus infection with significantly elevated viral titers and viral RNA levels following infection .

When selecting antibodies for AGO4 research, investigators should validate specificity against other Argonaute family members, particularly since compensation effects between AGO proteins have not been observed in knockout models, suggesting distinct functional roles .

How can researchers confirm AGO4 antibody specificity in experimental settings?

To confirm AGO4 antibody specificity, researchers should implement the following methodological approach:

• Western blot analysis using cells from wild-type and AGO4-knockout animals to verify absence of band in knockout samples

• Comparative blotting against recombinant AGO1-4 proteins to confirm lack of cross-reactivity

• Immunoprecipitation followed by mass spectrometry to validate pulled-down proteins

• Immunohistochemistry or immunofluorescence in wild-type versus knockout tissues to confirm signal specificity

• Peptide competition assays to demonstrate epitope-specific binding

Based on the research findings, AGO4 expression patterns vary across tissue types, with highest levels observed in adaptive immune cells, which should be considered when validating antibody performance in different experimental systems .

What are appropriate positive and negative controls when using AGO4 antibodies?

Positive Controls:

• Bone marrow-derived macrophages (BMDMs) from wild-type mice, which express detectable AGO4

• Adaptive immune cell populations with higher AGO4 expression levels

• Cells transfected with AGO4 expression constructs

Negative Controls:

• AGO4 knockout macrophages or other immune cells (critical for antibody validation)

• Cells treated with AGO4-specific siRNA to achieve knockdown

• Isotype-matched irrelevant antibodies to assess non-specific binding

Research demonstrates that AGO4 deficiency can be confirmed without evidence of compensatory expression of other AGOs, making knockout cells particularly valuable negative controls for antibody validation .

How can AGO4 antibodies be applied to investigate AGO4's role in IFN-dependent and IFN-independent antiviral mechanisms?

AGO4 exhibits both IFN-dependent and IFN-independent antiviral functions, making antibody-based methodologies particularly valuable for dissecting these dual mechanisms. Researchers should consider the following experimental approach:

• For IFN-dependent pathways:

  • Immunoprecipitate AGO4 following virus infection and analyze co-precipitated proteins involved in IFN signaling

  • Perform ChIP assays with AGO4 antibodies to identify potential association with IFN gene promoters

  • Use AGO4 antibodies in proximity ligation assays with IFN pathway components

• For IFN-independent mechanisms:

  • Conduct AGO4 immunoprecipitation in cells treated with IFNAR blocking antibodies (αIFNAR) or in IFNAR knockout backgrounds

  • Isolate and characterize AGO4-bound small RNAs in virus-infected cells with IFN signaling blocked

  • Compare AGO4-virus interactions in MAVS-deficient versus AGO4/MAVS double-deficient cells

Research has established that AGO4 deficiency further increases viral titers even in the absence of IFN signaling, demonstrating that AGO4 can elicit antiviral defense independently of, and in addition to, IFN .

What methodological considerations are important when using AGO4 antibodies to study virus-derived short interfering RNAs (vsiRNAs)?

When investigating AGO4-loaded vsiRNAs, a molecular marker of antiviral RNAi, researchers should implement the following methodology:

• Immunoprecipitation protocol optimization:

  • Use crosslinking methods (formaldehyde or UV) to stabilize AGO4-RNA interactions

  • Include RNase inhibitors throughout all purification steps

  • Perform stringent washing steps to remove non-specifically bound RNAs

• RNA extraction and analysis:

  • Extract small RNAs (<30 nt) from AGO4 immunoprecipitates

  • Perform small RNA sequencing with appropriate adapters for small RNA capture

  • Utilize bioinformatic tools to map recovered sequences to viral genomes

• Validation experiments:

  • Compare RNA profiles between wild-type and AGO4-deficient samples

  • Include non-infected controls to establish background binding

  • Use AGO1 or AGO3 immunoprecipitation as comparison controls

Studies have identified AGO-loaded vsiRNAs in macrophages infected with influenza or influenza lacking the IFN and RNAi suppressor NS1, which are uniquely diminished in the absence of AGO4 .

How can AGO4 antibodies be employed to investigate the molecular basis of AGO4's unique antiviral role compared to other Argonaute proteins?

To explore the molecular mechanisms behind AGO4's distinct antiviral function, researchers should consider these methodological approaches:

• Comparative interactome analysis:

  • Perform parallel immunoprecipitations with antibodies against each Argonaute protein

  • Conduct mass spectrometry to identify differential protein interactions

  • Validate key interactions through co-immunoprecipitation and western blotting

• Domain-specific investigations:

  • Use epitope-mapped antibodies targeting different regions of AGO4

  • Compare functional outcomes when different epitopes are bound

  • Apply domain-blocking antibodies to determine critical functional regions

• Subcellular localization studies:

  • Perform immunofluorescence to track AGO4 redistribution during viral infection

  • Compare with AGO1/AGO3 localization patterns under identical conditions

  • Use cell fractionation and subsequent western blotting to quantify distribution changes

Research demonstrates that overexpression of AGO4, but not AGO1 or AGO3, suppresses influenza in a dose-dependent manner, despite equal expression levels, suggesting that qualitative rather than quantitative differences determine AGO4's unique antiviral role .

What cell types and experimental systems are most appropriate for studying AGO4 function using antibody-based techniques?

When designing experiments involving AGO4 antibodies, researchers should consider the following cell types and systems based on demonstrated AGO4 functionality:

For optimal results in antibody-based experiments, researchers should:

• Validate AGO4 expression levels in their chosen cell type

• Consider the maturation state of immune cells, as no evidence of compromised maturation was observed in AGO4-deficient bone marrow-derived macrophages

• Include appropriate wild-type and knockout controls for each cell type

• Account for potential differences in AGO4 function between primary cells and cell lines

What are the methodological considerations for using AGO4 antibodies in live cell imaging experiments?

When conducting live cell imaging with AGO4 antibodies, researchers should implement the following methodological approach:

• Antibody modification:

  • Use Fab fragments rather than full IgG to minimize crosslinking effects

  • Employ site-specific labeling techniques to maintain antigen recognition

  • Validate that fluorophore conjugation doesn't alter binding properties

• Cell preparation:

  • Use minimal antibody concentrations to avoid perturbation of normal function

  • Optimize membrane permeabilization protocols if studying intracellular AGO4

  • Include non-expressing controls to establish background fluorescence levels

• Imaging parameters:

  • Employ rapid acquisition settings to capture dynamic AGO4 relocalization during viral infection

  • Use appropriate exposure times to minimize phototoxicity

  • Implement deconvolution algorithms to improve signal-to-noise ratio

• Data analysis:

  • Quantify colocalization with viral components or immune signaling molecules

  • Measure kinetics of AGO4 redistribution following infection

  • Compare patterns between AGO4 and other Argonaute proteins

This approach allows researchers to track AGO4 dynamics during viral infection while minimizing artifacts from the imaging methodology itself.

How can researchers effectively use AGO4 antibodies to study the relationship between AGO4 and interferon production?

AGO4 promotes IFN production following activation of antiviral pathways, unlike AGO1 or AGO3. To investigate this relationship, researchers should implement these methodological approaches:

• Chromatin immunoprecipitation (ChIP):

  • Use AGO4 antibodies to perform ChIP followed by qPCR or sequencing

  • Analyze AGO4 association with IFN gene promoters before and after viral stimulation

  • Compare binding patterns to transcription factors known to regulate IFN expression

• Protein complex analysis:

  • Immunoprecipitate AGO4 following viral infection or stimulation with viral ligands

  • Identify co-precipitated components of the RLR signaling pathway

  • Validate interactions through reciprocal immunoprecipitations

• Rescue experiments:

  • Introduce wild-type or mutant AGO4 into knockout cells using antibodies to confirm expression

  • Measure restoration of IFN-β production following infection with RNA viruses

  • Correlate IFN production with AGO4 localization using immunofluorescence

Research demonstrates that AGO4 knockout cells display a significant reduction in IFN-β following infection with a range of RNA viruses or stimulation with viral ligands, highlighting the importance of AGO4 in promoting IFN responses .

What protocols should be followed when using AGO4 antibodies in immunoprecipitation to isolate AGO4-associated RNAs?

To effectively isolate AGO4-associated RNAs, researchers should follow this optimized immunoprecipitation protocol:

• Cell preparation:

  • Crosslink cells with 0.1% formaldehyde or UV irradiation to stabilize RNA-protein complexes

  • Lyse cells in buffer containing RNase inhibitors and protease inhibitors

  • Clear lysates by centrifugation (16,000 × g, 10 minutes, 4°C)

• Immunoprecipitation:

  • Pre-clear lysate with protein A/G beads for 1 hour at 4°C

  • Incubate pre-cleared lysate with AGO4 antibody overnight at 4°C

  • Add protein A/G beads and incubate for 2-3 hours at 4°C

  • Wash extensively with high-stringency buffers to remove non-specific interactions

• RNA isolation:

  • Reverse crosslinks with proteinase K treatment

  • Extract RNA using TRIzol or similar reagent

  • Treat with DNase to remove contaminating DNA

  • Validate RNA quality using Bioanalyzer or similar platform

• Analysis options:

  • Small RNA sequencing for comprehensive profiling

  • Northern blotting for detection of specific viral RNAs

  • RT-qPCR for targeted analysis of candidate RNAs

This protocol enables identification of AGO-loaded virus-derived short interfering RNAs (vsiRNAs) in macrophages infected with influenza or influenza lacking NS1, which has been shown to be uniquely diminished in the absence of AGO4 .

How can researchers use AGO4 antibodies to investigate the interplay between AGO4 and viral immune evasion mechanisms?

To study how viruses might target or evade AGO4-mediated immunity, researchers should implement the following methodological approaches:

• Viral protein interaction studies:

  • Perform AGO4 immunoprecipitation during infection with wild-type versus mutant viruses

  • Compare binding profiles with viruses lacking specific immune evasion genes

  • Use proximity ligation assays to detect direct interactions between AGO4 and viral proteins

• AGO4 modification analysis:

  • Use AGO4 antibodies to immunoprecipitate AGO4 during infection

  • Analyze post-translational modifications using mass spectrometry

  • Compare modification patterns between uninfected and infected cells

• Localization studies:

  • Track AGO4 redistribution during infection using immunofluorescence

  • Compare AGO4 localization during infection with wild-type versus NS1-deficient influenza

  • Assess colocalization with viral replication complexes

Research indicates that influenza virus nonstructural protein 1 (NS1) represses both cognate siRNAs for antiviral RNAi and the IFN response, potentially targeting AGO4-dependent mechanisms .

What are common technical challenges when using AGO4 antibodies and how can they be addressed?

Researchers frequently encounter several challenges when working with AGO4 antibodies. Here are methodological solutions to common problems:

Researchers should also consider that AGO4 expression varies between cell types, with highest levels reported in adaptive immune cells, which may necessitate protocol adjustments when working with different cellular models .

How can researchers optimize immunohistochemistry protocols for AGO4 detection in tissue samples?

For effective AGO4 immunohistochemistry in tissue sections, researchers should implement the following methodological approach:

• Tissue preparation:

  • Fix tissues in 4% paraformaldehyde for optimal epitope preservation

  • Use antigen retrieval methods (citrate buffer, pH 6.0; 95°C for 20 minutes)

  • Block endogenous peroxidase activity with hydrogen peroxide solution

• Antibody application:

  • Optimize antibody dilution for each tissue type (typical range: 1:100-1:500)

  • Extend primary antibody incubation to overnight at 4°C

  • Use tyramide signal amplification systems for low-abundance detection

• Signal development:

  • Employ polymer-based detection systems rather than ABC methods

  • Optimize DAB development time to maximize signal-to-noise ratio

  • Use counterstains that don't obscure AGO4 localization patterns

• Controls and validation:

  • Include AGO4-knockout tissues as negative controls

  • Use tissues with known high AGO4 expression as positive controls

  • Perform peptide competition assays to confirm specificity

This protocol enables precise localization of AGO4 in tissue sections, allowing for correlation of expression patterns with physiological states or disease progression.